BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million

BioStem Technologies, Inc. (OTC: BSEM) is a company that develops and commercializes regenerative therapies using allografts made from perinatal tissue. The company recently reported record revenue and net income for the third quarter of 2024, driven by solid sales of its AmnioWrap2® product. The company also announced the nationwide launch of its Vendaje AC® product and initiated clinical trials to study the efficacy of its products in treating diabetic foot ulcers and venous leg ulcers. BioStem Technologies has also filed a registration statement with the Securities and Exchange Commission and applied for NASDAQ uplisting, signaling its intention to obtain a national stock listing.